Large scale multiplexed experiments assessing cells and proteins of the immune system are critical to understanding and advancement of immunotherapy treatment for cancer and other diseases.
This webinar will highlight:
- How current challenges in antibody screening workflows can be overcome by the iQue Screener’s ability to simultaneously screen cells and proteins in suspension
- How users of our technology have advanced their research by benefiting from fast time to results, miniaturized assays, flexibility and choice in content and multiplexing
- Key cell and bead based applications run on the iQue Screener including: evaluation of cell killing mechanism, screening for immune checkpoint inhibitors and more.
Tom Duensing, CTO, IntelliCyt Corporation.
Belen Ybarrondo, Adjunct Faculty, San Diego Community College.